Vitamin D in a migraine pilot: frequency changed, severity did not

The study and its comparison

Forty-eight adults with migraine were randomized after a four-week baseline period to vitamin D3 or placebo for twenty-four weeks. The research amount was 100 micrograms, equivalent to 4,000 IU, daily. [1]

Headache days declined from about 6.1 to 3.3 in the vitamin group and 5.7 to 4.9 with placebo; the frequency comparison favored vitamin D. Severity, pain thresholds and temporal summation did not significantly improve. [1]

What the finding establishes

A small single study needs confirmation and does not show that a new headache is caused by deficiency. Its research dose is not an individual recommendation. Funding and conflicts were not established from the retrieved abstract. Frequency and intensity should be reported separately. [1]

A hypothetical distinction

Imagine headaches occur less often but hurt just as much when present. Those are different outcomes.

Interpretation checklist — Vitamin D in a migraine pilot
Detail	Interpretation
Measured outcome	Keep the endpoint specific
Study preparation	Not every retail product
Remaining uncertainty	Not resolved by a mechanism

Vitamin D in a migraine pilot: frequency changed, severity did not — original article outline diagram — Original editorial diagram of this article’s sections; no product photograph or clinical finding is depicted.

Sources for this article

A randomized, double-blinded, placebo-controlled, parallel trial of vitamin D 3 supplementation in adult patients with migraine.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.